keyword
MENU ▼
Read by QxMD icon Read
search

Intravesical BCG

keyword
https://www.readbyqxmd.com/read/28041998/bacillus-calmette-guerin-strain-may-not-effect-recurrence-free-survival-when-used-intravesically-with-interferon-alpha2b-for-non-muscle-invasive-bladder-cancer
#1
Ryan L Steinberg, Nathan A Brooks, Lewis J Thomas, Sarah L Mott, Michael A O'Donnell
OBJECTIVES: Adjuvant intravesical Bacillus Calmette-Guerin (BCG) remains the standard-of-care for high-grade non-muscle-invasive bladder cancer (NMIBC). Conflicting reports exist regarding disparate outcomes among BCG strains. We sought to determine whether a difference in recurrence-free survival (RFS) existed between TICE BCG and Connaught BCG strains used with interferon (IFN) for the treatment of NMBIC. MATERIALS AND METHODS: A post hoc analysis of the phase 2 BCG/IFN study, conducted from May 1999 to February 2001...
December 29, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/28027868/intravesical-therapy-for-the-treatment-of-non-muscle-invasive-bladder-cancer-a-systematic-review-and-meta-analysis
#2
REVIEW
Roger Chou, Shelley Selph, David I Buckley, Rongwei Fu, Jessica C Griffin, Sara Grusing, John L Gore
PURPOSE: To systematically review benefits and harms of intravesical therapies for NMIBC. METHODS: Systematic literature searches of Ovid MEDLINE (January 1990 through February 2016), the Cochrane databases, and reference lists were performed. Randomized and quasi-randomized trials of intravesical bacillus Calmette-Guérin [BCG], mitomycin C [MMC], gemcitabine, thiotepa, valrubicin, doxorubicin, epirubicin, and interferon versus TURBT alone, and head-to-head trials of intravesical therapies...
December 24, 2016: Journal of Urology
https://www.readbyqxmd.com/read/28010156/bacillus-calmette-gu%C3%A3-rin-infection-and-cytotoxicity-in-the-retinal-pigment-epithelium
#3
Victor Llorenç, Marina Mesquida, Blanca Molins, Julian Gonzalez-Martín, Maite Sainz de la Maza, Alfredo Adán
PURPOSE: To investigate bacillus Calmette-Guérin (BCG) infective capability and cytotoxicity in ARPE-19 cells. METHODS: BCG inoculum was dispensed at a MOI 100:1 for 3 h in 90% confluent ARPE-19 cells. Infection rates at different time points were determined by colony forming units (CFU) count and, in parallel, by the number of microscopically infected cells. WST-1 reagent was used for cytotoxicity assays. RESULTS: A 67-year-old man previously treated with intravesical BCG for bladder carcinoma presented with chronic, refractory, bilateral uveitis with macular edema...
December 23, 2016: Ocular Immunology and Inflammation
https://www.readbyqxmd.com/read/28005163/intratumoral-th2-predisposition-combines-with-an-increased-th1-functional-phenotype-in-clinical-response-to-intravesical-bcg-in-bladder-cancer
#4
Renate Pichler, Georg Gruenbacher, Zoran Culig, Andrea Brunner, Dietmar Fuchs, Josef Fritz, Hubert Gander, Andrea Rahm, Martin Thurnher
Th1-type immunity is considered to be required for efficient response to BCG in bladder cancer, although Th2 predisposition of BCG responders has recently been reported. The aim was to evaluate the relationship of Th1 and Th2 components in 23 patients undergoing BCG treatment. Peripheral blood, serum and urine samples were prospectively collected at baseline, during and after BCG. Th1 (neopterin, tryptophan, kynurenine, kynurenine-to-tryptophan ratio (KTR), IL-12, IFN-γ, soluble TNF-R75 and IL-2Rα) and Th2 (IL-4, IL-10) biomarkers as well as CD4 expression in T helper (Th), effector and regulatory T cells were determined...
December 22, 2016: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/27960233/iatrogenic-changes-in-the-urinary-tract
#5
REVIEW
Antonio Lopez-Beltran, Gladell P Paner, Rodolfo Montironi, Maria R Raspollini, Liang Cheng
A handful of therapeutic procedures are used to treat malignancies of the urinary tract, most frequently intravesical immunotherapy or chemotherapy, but also neoadjuvant systemic chemotherapy. These treatment modalities produce morphological changes in the urothelium that can be mistaken for carcinoma; in particular, these therapies frequently mimic urothelial carcinoma in situ (CIS) urothelial dysplasia or true invasive neoplasia. Drugs such as mitomycin C used after transurethral resection of bladder tumour to reduce recurrences, bacillus Calmette-Guérin (BCG) intravesical immunotherapy to treat high-risk non-muscle-invasive bladder cancer and urothelial CIS and platin-based systemic chemotherapy to improve postcystectomy disease-specific survival are examples of therapy-related atypia seen in the urinary tract...
January 2017: Histopathology
https://www.readbyqxmd.com/read/27932416/a-phase-ii-trial-of-dovitinib-in-bcg-unresponsive-urothelial-carcinoma-with-fgfr3-mutations-or-over-expression-hoosier-cancer-research-network-trial-hcrn-12-157
#6
Noah M Hahn, Trinity J Bivalacqua, Ashley E Ross, George J Netto, Alexander S Baras, Jong Chul Park, Carolyn Chapman, Timothy A Masterson, Michael O Koch, Richard Bihrle, Richard S Foster, Thomas A Gardner, Liang Cheng, David R Jones, Kyle McElyea, George E Sandusky, Timothy Breen, Ziyue Liu, Costantine Albany, Marietta L Moore, Rhoda A Loman, Angela Reed, Scott A Turner, Francine B de Abreu, Torrey L Gallagher, Gregory J Tsongalis, Elizabeth R Plimack, Richard E Greenberg, Daniel M Geynisman
PURPOSE: To assess the clinical and pharmacodynamic activity of dovitinib in a treatment resistant, molecularly enriched NMIUC population. EXPERIMENTAL DESIGN: A multi-site pilot phase 2 trial was conducted. Key eligibility criteria included: BCG unresponsive NMIUC (> 2 prior intravesical regimens) with increased phosphorylated FGFR3 (pFGFR3) expression by centrally analyzed immunohistochemistry (IHC+) or FGFR3 mutations (Mut+) assessed in a CLIA-licensed laboratory...
December 8, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/27903467/arteriocutaneous-fistula-associated-with-bilateral-femoral-pseudoaneurysms-caused-by-bacillus-calmette-gu%C3%A3-rin-apropos-of-a-case-and-review-of-literature
#7
Álvaro Torres-Blanco, Francisco Gómez-Palonés, Gemma Edo-Fleta
Vascular complications of intravesical instillation of bacillus Calmette-Guérin (BCG) are rare. BCG is an attenuated strain of Mycobacterium bovis that was initially developed for vaccination against tuberculosis, but it has also been used as an adjuvant treatment for bladder transitional carcinoma. We report a patient with a history of instillation of BCG 2 years before, who underwent surgical treatment of 2 pseudoaneurysms. The first, located in the left superficial femoral artery (SFA), was resected, and the artery was ligated because he had a history of femoropopliteal occlusion...
November 27, 2016: Annals of Vascular Surgery
https://www.readbyqxmd.com/read/27893591/endophthalmitis-in-a-patient-treated-with-bacillus-calmette-gu%C3%A3-rin-immunotherapy
#8
Julie Vadboncoeur, Sébastien Olivier, Hafid Soualhine, Annie-Claude Labbé, Marie-Lyne Bélair
BACKGROUND: Intravesical Bacillus Calmette-Guérin (BCG) instillation has become one of the mainstays of adjunctive therapy in the treatment of superficial bladder cancer. Ophthalmologic complications are rare, but few cases are reported in the literature. METHODS: Retrospective observational case report. RESULTS: The authors report a case of unilateral Mycobacterium bovis BCG endophthalmitis after intravesical BCG instillations. Despite appropriate systemic antituberculous and corticosteroid therapy, the patient almost completely lost sight in the affected eye...
November 23, 2016: Retinal Cases & Brief Reports
https://www.readbyqxmd.com/read/27885456/-intravesical-radioimmunotherapy-of-carcinoma-in-situ-of-the-urinary-bladder-after-bcg-failure
#9
M E Autenrieth, T Horn, F Kurtz, K Nguyen, A Morgenstern, F Bruchertseifer, M Schwaiger, M Blechert, C Seidl, R Senekowitsch-Schmidtke, J E Gschwend, K Scheidhauer
BACKGROUND: In failure to respond to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ (CIS) of the urinary bladder, radical cystectomy remains the mainstay after BCG failure. OBJECTIVES: The aim of this pilot study was to evaluate tolerability and safety of the α‑emitter radioimmunoconjugate instillation in patients after BCG failure. MATERIALS AND METHODS: Nine patients were included. After emptying the bladder via a transurethral catheter, Bi-213-anti-EGFR-mAb was instilled...
November 24, 2016: Der Urologe. Ausg. A
https://www.readbyqxmd.com/read/27884539/intravesical-chemotherapy-use-after-radical-nephroureterectomy-a-national-survey-of-urologic-oncologists
#10
Diane D Lu, Stephen A Boorjian, Jay D Raman
: To determine the use of prophylactic intravesical chemotherapy (pIVC) following radical nephroureterectomy (RNU) and barriers to utilization in a survey study of urologic oncologists. METHODS: A survey instrument was constructed, which queried respondents on professional experience, practice environment, pIVC use, and reasons for not recommending pIVC when applicable. The survey was electronically distributed to members of the Society of Urologic Oncology over an 8-week period...
November 21, 2016: Urologic Oncology
https://www.readbyqxmd.com/read/27846935/-ccafu-french-national-guidelines-2016-2018-on-bladder-cancer
#11
M Rouprêt, Y Neuzillet, A Masson-Lecomte, P Colin, E Compérat, F Dubosq, N Houédé, S Larré, G Pignot, P Puech, M Roumiguié, E Xylinas, A Méjean
OBJECTIVE: The purpose of the guidelines national committee CCAFU on bladder cancer was to propose updated french guidelines for non-muscle invasive (NMIBC) and invasive (MIBC) bladder cancers. METHODS: A Medline search was achieved between 2013 and 2016, as regards diagnosis, options of treatment and follow-up of bladder cancer, to evaluate different references with levels of evidence. RESULTS: Diagnosis of NMIBC (Ta, T1, CIS) is based on a complete deep resection of the tumour...
November 2016: Progrès en Urologie
https://www.readbyqxmd.com/read/27800054/administration-of-mycobacterium-phlei-cell-wall-nucleic-acid-complex-in-the-immediate-postoperative-period-for-the-treatment-of-non-muscle-invasive-bladder-cancer
#12
Álvaro Morales
INTRODUCTION: This review sought to investigate the safety of intravesical administration of Mycobacterium phlei cell wall-nucleic acid (MCNA) in the immediate postoperative period after biopsy/resection for non-muscle-invasive bladder cancer (NMIBC). METHODS: Patients with NMIBC who failed bacillus Calmette-Guérin (BCG) therapy and at high risk of recurrence and progression participated in this study. Treatment involved an induction phase of six weeks and maintenance of three weekly instillations every six months for two years...
September 2016: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/27788495/evaluating-the-efficacy-and-safety-of-intravesical-chemotherapies-for-non-muscle-invasive-bladder-cancer-a-network-meta-analysis
#13
Chuanjun Zhuo, Xubin Li, Hongqing Zhuang, Shunli Tian, Hailong Cui, Ronghuan Jiang, Chuanxin Liu, Ran Tao, Xiaodong Lin
Various intravesical therapies have been introduced into clinical practices for controlling non-muscle invasive bladder cancer (NMIBC). However, evidence with respect to the efficacy and safety of those intravesical therapies is very limited. Hence, we present a network meta-analysis in order to address this limitation in the current literature. The primary outcomes were the risk of tumor recurrence (TR), tumor progression (TP) and disease-specific mortality (DM). Secondary outcomes included the risk of fever, cystitis and haematuria...
October 24, 2016: Oncotarget
https://www.readbyqxmd.com/read/27768213/radiofrequency-induced-thermo-chemotherapy-effect-rite-for-non-muscle-invasive-bladder-cancer-treatment-current-role-and-perspectives
#14
Renzo Colombo, Hans van Valenberg, Marco Moschini, Johannes A Witjes
OBJECTIVE: An updated review of intravesical radiofrequency (RF)-induced thermo-chemotherapy effect (RITE) for NMIBC with regard to efficacy, adverse events (AEs) and perspectives. EVIDENCE ACQUISITION: An extensive and sensitive search for RF-induced chemo-hyperthermia in Medline, Embase, Cochrane and ClinicalTrials.gov databases was performed. A table of published clinical trials up to 2016 was constructed. No meta-analysis could be performed on the basis of new papers...
October 4, 2016: Urologia
https://www.readbyqxmd.com/read/27761190/left-anterior-descending-coronary-artery-and-multiple-peripheral-mycotic-aneurysms-due-to-mycobacterium-bovis-following-intravesical-bacillus-calmette-guerin-therapy-a-case-report
#15
Petar Duvnjak, Mario Laguna
The use of live attenuated intravesicular Bacillus Calmette-Guerin (BCG) therapy is a generally accepted safe and effective method for the treatment of superficial transitional cell carcinoma (TCC) of the bladder. Although rare, < 5% of patient's treated with intravesicular BCG therapy may develop potentially serious complications, including localized infections to the genitourinary tract, mycotic aneurysms and osteomyelitis. We present here a case of a 63-year-old male who developed left coronary and multiple peripheral M...
August 2016: Journal of Radiology Case Reports
https://www.readbyqxmd.com/read/27750214/genomic-characterization-of-high-risk-non-muscle-invasive-bladder-cancer
#16
Joshua J Meeks, Benedito A Carneiro, Sachin G Pai, Daniel T Oberlin, Alfred Rademaker, Kyle Fedorchak, Sohail Balasubramanian, Julia Elvin, Nike Beaubier, Francis J Giles
The genetic mechanisms associated with progression of high-risk non-muscle-invasive bladder cancer (HR-NMIBC) have not been described. We conducted selective next-generation sequencing (NGS) of HR-NMIBC and compared the genomic profiles of cancers that responded to intravesical therapy and those that progressed to muscle-invasive or advanced disease. DNA was extracted from paraffin-embedded sections from 25 HR-NMIBCs (22 with T1HG; 3 with TaHG with or without carcinoma in situ). Ten patients with HR-NMIBC developed progression (pT2+ or N+) ("progressors")...
October 14, 2016: Oncotarget
https://www.readbyqxmd.com/read/27716887/intravesical-electro-osmotic-administration-of-mitomycin-c
#17
Savino M Di Stasi, Cristian Verri, Francesco Celestino, Francesco De Carlo, Vincenzo Pagliarulo
Bladder cancer is very common and most cases are diagnosed as nonmuscle invasive disease, which is characterized by its propensity to recur and progress. Intravesical therapy is used to delay recurrence and progression, while cystectomy is reserved for patients who are refractory to transurethral resection and intravesical therapy. There is an increasing interest in methods to enhance the delivery of intravesical chemotherapeutic agents to improve efficacy. In vitro and in vivo studies demonstrated that electro-osmosis of mitomycin C (MMC) is more effective in delivering this drug into the urothelium, lamina propria, and superficial muscle layers of the bladder wall than is passive transport...
October 4, 2016: Urologia
https://www.readbyqxmd.com/read/27716885/mitomycin-c-from-birth-to-adulthood
#18
Vincenzo Serretta, Cristina Scalici Gesolfo, Vincenza Alonge, Fabrizio Di Maida, Giovanni Caruana
Mitomycin C (MMC) intravesical therapy for "superficial" papillary bladder tumors was firstly introduced in the early seventies with promising results. In the following years, several pharmacokinetic studies investigated its mechanism of action to optimize the intravesical administration. Numerous studies confirmed thereafter both the ablative and the prophylactic efficacy and the low toxicity of MMC when intravesically given. In 1984, a complete response rate of 42% in 60 patients not responsive to thiotepa was reported with intravesical MMC at the dose of 40 mg diluted in 40 ml for 8 weeks...
October 4, 2016: Urologia
https://www.readbyqxmd.com/read/27712914/-intravesical-instillations-in-non-muscle-invasive-bladder-cancer-nmibc-prospects-for-thermochemotherapy
#19
J Irani
: Non-muscle-invasive bladder cancer (NMIBC) is characterised by a high risk of recurrence when performing only a transurethral resection of the bladder (TURB). Intravesical instillations are performed postoperatively to decrease the rate of recurrence. The standard agents currently used are Mitomycin-C (MMC) or bacillus Calmette-Guérin (BCG). In order to further enhance the efficacy of the adjuvant treatments and/or diminish their side effects, alternative treatments are studied. Intravesical MMC combined with hyperthermia could be an interesting alternative active treatment for intermediate- and possibly high-risk NMIBC, and has been investigated in the past years...
November 2016: Progrès en Urologie
https://www.readbyqxmd.com/read/27701987/efficacy-and-safety-of-bladder-hydrodistension-for-decreased-bladder-capacity-induced-by-intravesical-bcg-therapy
#20
Kazuyuki Numakura, Norihiko Tsuchiya, Hiroshi Tsuruta, Susumu Akihama, Mitsuru Saito, Takamitsu Inoue, Shintaro Narita, Mingguo Huang, Shigeru Satoh, Tomonori Habuchi
OBJECTIVE: Intravesical BCG therapy is widely used for the treatment of high-risk, non-muscle-invasive bladder cancer. Among various reported side-effects, decreased bladder capacity is a serious side-effect that significantly worsens patients' quality of life. This article reports the efficacy and safety of bladder hydrodistension (BHD) in six patients with seriously decreased bladder capacity caused by BCG treatment. METHODS: Six patients with low bladder capacity (<100 ml in voiding diaries) and complaint of grade 3 irritative symptoms were diagnosed with decreased bladder capacity and treated with BHD...
December 2016: Scandinavian Journal of Urology
keyword
keyword
7101
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"